×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CADL – candel therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CADL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/17
09:58 am
cadl
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 [Yahoo! Finance]
Low
Report
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 [Yahoo! Finance]
3/17
08:29 am
cadl
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors [Yahoo! Finance]
Low
Report
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors [Yahoo! Finance]
3/17
08:05 am
cadl
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Medium
Report
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
3/13
04:22 pm
cadl
Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
Medium
Report
Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
3/13
02:48 pm
cadl
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
Low
Report
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
3/12
09:47 am
cadl
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]
Low
Report
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]
3/12
08:05 am
cadl
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Low
Report
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
3/11
07:18 am
cadl
Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".
Date
Time
Symbol
Company Name
Action
%Chg
3/12/2026
08:05 am
cadl
candel therapeutics, inc.
MISS
Report
-0.4%
candel therapeutics, inc.
11/13/2025
08:25 am
cadl
candel therapeutics, inc.
MISS
Report
-8.3%
candel therapeutics, inc.
8/14/2025
08:05 am
cadl
candel therapeutics, inc.
BEAT
Report
-5.0%
candel therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/18
04:23 pm
cadl
Form SCHEDULE 13D/A Candel Therapeutics, Filed by: Manning Paul B
Low
Report
Form SCHEDULE 13D/A Candel Therapeutics, Filed by: Manning Paul B
3/12
08:17 am
cadl
Form 10-K Candel Therapeutics, For: Dec 31
Low
Report
Form 10-K Candel Therapeutics, For: Dec 31
3/12
08:10 am
cadl
Form 8-K Candel Therapeutics, For: Mar 12
Medium
Report
Form 8-K Candel Therapeutics, For: Mar 12
2/26
07:39 pm
cadl
Form 4 Candel Therapeutics, For: Feb 23 Filed by: Manning Paul B
Low
Report
Form 4 Candel Therapeutics, For: Feb 23 Filed by: Manning Paul B
2/23
08:00 am
cadl
Form 8-K Candel Therapeutics, For: Feb 19
Low
Report
Form 8-K Candel Therapeutics, For: Feb 19
2/20
04:16 pm
cadl
Form 424B5 Candel Therapeutics,
Low
Report
Form 424B5 Candel Therapeutics,
2/19
04:32 pm
cadl
Form 424B5 Candel Therapeutics,
Medium
Report
Form 424B5 Candel Therapeutics,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: